Complete resolution of leukemia cutis with sorafenib in an acute myeloid leukemia patient with FLT3-ITD mutation

American Journal of Hematology

Volumn 84, Issue 10, 2009, Pages 701-702

  Sung, Ho Lee ^a   Paietta, Elisabeth ^a   Racevskis, Janis ^a   Wiernik, Peter H ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZACITIDINE; CD135 ANTIGEN; SORAFENIB;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; AGED; BONE MARROW BIOPSY; CASE REPORT; CYTOGENETICS; HUMAN; LABORATORY TEST; LETTER; LEUKOCYTE COUNT; MALE; MITRAL VALVE REGURGITATION; PAPULE; PRIORITY JOURNAL; SKIN BIOPSY; SKIN DEFECT; SKIN LEUKEMIA; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOID, ACUTE; LEUKEMIC INFILTRATION; MALE; MUTATION; PYRIDINES; SKIN; TANDEM REPEAT SEQUENCES; TREATMENT OUTCOME;

EID: 70349487716     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21511     Document Type: Letter

References (8)

1. Zhang W, Konopleva M, Shi YX, et al. Mutant FLT3: A direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst 2008;100:184-198.
2. Paietta E, Andersen J, Yunis J, et al. Acute myeloid leukemia expressing the leucocyte integrin CD11b - A new leukemic syndrome with poor prognosis: Result of an ECOG database analysis. Br J Haematol 1998;100:265-272. (Pubitemid 28131056)
3. Nakao M, Yokota S, Iwai T, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996;10:1911-1918. (Pubitemid 27019637)
4. Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the United Kingdom medical research council AML 10 and 12 trials. Blood 2001;98:1752-1759.
5. Safaian NN, Czibere A, Bruns I, et al. Sorafenib (Nexavar®) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD acute myeloid leukemia. Leuk Res 2009;33:348-350.
6. Metzelder S, Wang Y, Wollmer E, et al. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: Sustained regression before and after allogenic stem cell transplantation. Blood 2009;113:6567-6571.
7. Hu S, Niu H, Minkin P, et al. Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia. Mol Cancer Ther 2008;7:1110-1120.
8. Zhang W, Konopleva M, Ruvolo VR, et al. Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. Leukemia 2008;22:808-818. (Pubitemid 351552630)